Interleukin 17A Genotype

IL-17A is one of the immune signals that calls inflammation into tissue. Some IL17A variants, especially rs2275913 A in cell studies, have been linked to higher IL-17A output after a trigger, though the direction depends on tissue and disease. That can tilt the odds of stronger inflammatory responses in the mouth, gut, joints, skin, and some infections.

This test reads the DNA sequence at the IL17A gene from cells in your saliva. It is a one-time read of an inherited setting, not a snapshot of how much IL-17A your body is producing right now. The result is exploratory. It tells you something about tendency, not about a diagnosis.

What This Test Actually Reads

IL-17A is a cytokine. Cytokines are small proteins immune cells use to send instructions. Th17 cells are one main source. Several fast-response immune cells can make it too.

When IL-17A lands on cells lining the mouth, gut, skin, or airways, and on repair cells in connective tissue, it triggers other chemical signals that call in white blood cells. It also turns on tissue-remodeling enzymes. That response helps protect body surfaces against Candida and other microbes. Too much of the same response can damage tissue.

The IL17A gene sits on chromosome 6p12. Small single-letter variants in and around this gene can change how much protein your cells make in response to a given trigger. The most studied variant is rs2275913, sometimes written as G-197A. It is in the promoter region. A promoter is a control region that helps decide how strongly a gene is switched on. Other studied variants include rs8193038, rs3819024, and rs4711998. Different variants carry different weight in different populations.

A saliva sample gives the lab enough cheek and white blood cells to read your DNA at these positions. The DNA itself will be the same next year and thirty years from now. If a result ever changes, think sample quality or assay difference, not biology.

Where This Marker Sits Clinically

This is a research-tier marker. There are no standardized clinical cutoffs, no clinical guideline that tells you what to do with a specific genotype call, and no drug prescribed on the basis of an IL17A polymorphism. The evidence linking specific variants to specific outcomes comes mostly from case-control studies in single populations. A carrier is at somewhat higher statistical risk of certain inflammatory conditions, not destined for them.

Two things follow from that. First, the result is most useful as one input in a broader picture that includes family history, symptoms, and standard labs. Second, most people who carry a higher-inflammation variant never develop any of the diseases it has been linked to. A risk variant does not act like a switch. Other genes, infections, exposures, and habits do a lot of the work.

Cancer Susceptibility

The rs2275913 A allele has been linked to higher colorectal cancer risk in a 2022 meta-analysis of 10 case-control studies covering roughly 2,599 cases and 2,845 controls. The colorectal signal is less consistent than the gastric one: at least one digestive-neoplasm meta-analysis found rs2275913 tied to gastric cancer but not colorectal cancer. Gastric cancer data point in the same direction across multiple meta-analyses. In one Iranian study, people with AA at -197 had about three times the odds of gastric cancer compared with GG. Carrying at least one A allele was a smaller signal, about 1.6 times the odds. A related variant, rs10484879, tracked with family history of colorectal cancer and with stage at diagnosis in a Tunisian case-control study.

These are association findings, not screening tools. They do not tell you whether you have cancer, and they do not replace colonoscopy or upper endoscopy. They add weight to being strict about screening you already qualify for, and faster about GI symptoms or a strong family history. They do not create a new screening schedule by themselves.

Autoimmune and Inflammatory Disease

IL-17A is one of the best-tested inflammatory signals in psoriasis, psoriatic arthritis, and ankylosing spondylitis. Drugs that block IL-17A are used for those diagnoses, but they are prescribed for diagnosed disease, not for a genotype. IL-17A inhibitors are not effective in inflammatory bowel disease, so an IL17A variant does not translate into a treatment plan.

IL17A variants have been linked to oral lichen planus. In a Brazilian cohort, carriers of the G197A GA or AA genotype had about 3.4 times the odds of disease. Ulcerative colitis evidence is strongest in Asian studies, though even within that literature the direction is not uniform: a Korean study reported the -197A allele as protective for UC (odds ratio about 0.63). Finnish studies have linked rs2275913 with juvenile idiopathic arthritis and with osteitis after BCG vaccination.

The rheumatoid arthritis evidence is genuinely contradictory rather than merely mixed. A Tunisian study found that IL17A and IL17RC polymorphisms did not predict who had RA, though plasma IL-17A protein levels tracked disease activity in those already diagnosed. An Egyptian study implicated the G allele and GG genotype in higher IL-17A levels and greater disease severity. Yet a pooled meta-analysis found the A allele raised RA risk by roughly 20 to 41 percent. Read this as unresolved: the direction of any IL17A effect in RA depends on population and outcome measured.

Metabolic and Cardiovascular Risk

MASLD is the newer name for what used to be called non-alcoholic fatty liver disease. An exploratory Romanian study with fewer than 100 participants found IL17A-G197A variant genotypes were far more common in metabolic-associated steatohepatitis than controls, about tenfold higher odds in an unadjusted model. The broader MASLD signal was weaker after correction, so this is a lead, not a risk test.

In Mexican patients, two IL17A haplotypes were associated with premature coronary artery disease, but no single IL17A variant predicted CAD on its own. These findings point to IL-17A-driven inflammation as one possible route into fatty liver and early heart disease. Standard lipid, glucose, and liver panels still do the heavy lifting.

Infection Response

IL-17A helps keep fungi in check at mucosal surfaces, so genetic settings that lower IL-17A signaling can leave people more prone to oral candidiasis. In a Senegalese severe malaria cohort, carriers of the rs8193038 AG genotype had higher serum IL-17A, and IL-17A levels were lower in those who died than in survivors. In COVID-19, the GA genotype at rs2275913 was linked to about half the odds of severe disease in an Iranian sample.

These findings can pull in opposite directions. IL-17A is protective at the right dose and harmful in excess, and the same variant can look helpful in one infection and neutral or harmful in another. A specific genotype is not simply good or bad. Its meaning depends on the tissue and trigger.

Reading a Result That Cuts Both Ways

The link between the rs2275913 A allele and higher IL-17A production is best supported in stimulated T-cell experiments, but it does not hold uniformly across diseases and tissues. In Egyptian rheumatoid arthritis patients, the GG genotype was tied to higher serum IL-17A. In a syphilis cohort, genotype and IL-17A levels showed no clear correlation. In colorectal cancer, one report found genotype did not influence serum IL-17A. So the same variant can push levels up in one setting, down in another, or track with nothing measurable.

Higher IL-17A output is not simply good or bad either. A setting that turns up mucosal defense may help you clear a fungus and hurt you if that same inflammation attacks your joints or gut. A single genotype call cannot drive a decision on its own. Read it alongside what your body is actually doing: symptoms, standard inflammatory markers, and family history of the specific diseases linked to the variant.

When the Result Can Mislead

Interpret the result with these limits in mind.

• Variant coverage: the assay reads specific positions in the IL17A gene. A negative result rules out those variants, not every possible variant in the gene.
• Ancestry matters: several IL17A variants are more common in some populations than others, and the disease associations found in one ethnic group may not carry the same weight in another.
• Uncertain variants: occasionally a rare change turns up whose clinical meaning is unknown. That is a fact about the current evidence, not a diagnosis.
• Inherited versus acquired DNA: this result is meant to read DNA you were born with. If a result conflicts with family history or another lab, confirm it with a clinical-grade test from a fresh sample.
• Clinical-grade versus consumer tests: direct-to-consumer raw data may use a different chip and weaker quality filters. Treat a high-impact consumer result as a lead until it is confirmed.
• Sample cellularity: saliva collection can yield too few cells for a confident read. If that happens, the lab may ask for a repeat sample.

One-Time Test, Lifelong Use

Your IL17A genotype does not change. There is no reason to repeat this test once you have a confident clinical-grade result. What can change is what you do with it. If you carry a variant linked to higher inflammatory drive, the value comes from folding that into decisions you make over years: screening you already qualify for, quicker follow-up on symptoms, and family conversations.

The tests to repeat are companion phenotype tests, not IL17A. If you carry a variant linked to colorectal cancer risk, stay on the recommended colonoscopy schedule and do not stretch the interval. If you carry variants linked to fatty liver or early coronary disease, an annual metabolic and lipid panel with ApoB is a reasonable baseline. If symptoms point to an inflammatory condition your variant is associated with, escalate faster to a specialist than you otherwise might.

What to Do With a Positive Result

A positive call is a reason to look, not to panic. Confirm a high-impact or surprising result with a clinical-grade assay from a fresh sample before it changes screening or family testing. Then pair the genotype with a phenotype workup. If the variant is associated with a specific cancer, get on schedule with the relevant screening. If it is associated with an autoimmune or inflammatory condition, track markers like hs-CRP and ESR annually and get new joint, skin, or gut symptoms evaluated early.

Talk with biological family members. First-degree relatives share, on average, half your DNA, so a variant that raises your risk may matter for them too. That is often the highest-value action from a positive result, because it can change screening decisions across a family.

A genetic counselor can help if the result is confusing, if family history is strong, or if relatives are deciding whether to test. That is especially useful when the variant is rare, ancestry-specific, or reported differently across labs.